Concepedia
Statistics
Publications
9
Citations
438
H-Index
Active since
2016
Affiliations
Seoul National University Bundang Hospital(Current)
Chungbuk National University Hospital
Seoul National University Hospital
Japanese Foundation For Cancer Research
Samsung Medical Center
J.-S. Lee is an author at Seoul National University Bundang Hospital specializing in oncology, medicine, and cancer immunotherapy.
Publications per year
2016–2023
Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer
Shunichi Sugawara, J.-S. Lee, Jin‐Hyoung Kang et al. · Annals of Oncology · 2021 · 199 citations · Full text
Medicine, Oncology, Pharmacotherapy +17
IMpower133: Updated overall survival (OS) analysis of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC)
M. Reck, Stephen V. Liu, Aaron S. Mansfield et al. · Annals of Oncology · 2019 · 68 citations · Full text
Medicine, Oncology, Pharmacology +8
1300: Efficacy and safety of BI 1482694 (HM61713), an EGFR mutant-specific inhibitor, in T790M-positive NSCLC at the recommended phase II dose
K. Park, J.-S. Lee, J. Y. Han et al. · Journal of Thoracic Oncology · 2016 · 38 citations · Full text
Medicine, Oncology, Pharmacology +11
OA01.04 Five-Year Survival in Patients with ES-SCLC Treated with Atezolizumab in IMpower133: Imbrella a Extension Study Results
Stephen V. Liu, Rafał Dziadziuszko, Shunichi Sugawara et al. · Journal of Thoracic Oncology · 2023 · 36 citations · Full text
Medicine, Oncology, Pharmacology +5
Phase II study of osimertinib in NSCLC patients with EGFR exon 20 insertion mutation: A multicenter trial of the Korean Cancer Study Group (LU17-19)
T.M. Kim, Chan‐Young Ock, M. Kim et al. · Annals of Oncology · 2019 · 34 citations · Full text
Medicine, Molecular Genetics, Oncology +14
1–5 of 9